| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| N411994-1mg | 1mg |
现货  |
| |
| N411994-5mg | 5mg |
现货 |
| |
| N411994-10mg | 10mg |
现货 |
|
| 产品名称 | Nivolumab (anti-PD-1) |
|---|---|
| 规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG4SP; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
| 特异性 | PDCD1/PD-1/CD279 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 反应种属 | Cynomolgus,Human |
| 偶联标记 | Unconjugated |
| 抗体类型 | Primary antibody |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG4SP |
| 轻链亚型 | Kappa |
| SDS-PAGE | 26.4 kDa (Light Chain) & 53.3 kDa (Heavy Chain), under reducing conditions; 178.6 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | Lot by Lot |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | Store at -80℃ for 18 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS编号和信息 | 946414-94-4 |
| IMGT/mAb-DB | 424 |
|---|---|
| Wikipedia | nivolumab |
| PubChem SID | 178103907 |
| Reactome Reaction | R-HSA-9679421 |
| Reactome Drug | R-ALL-9679411 |
| PEP | nivolumab |
| Target ID | 2760 | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 名称 | programmed cell death 1 (CD279) | ||||||||||||||||||||||||
| 缩写名 | PD-1 | ||||||||||||||||||||||||
| 家族 | Other immune checkpoint proteins | ||||||||||||||||||||||||
| 别名 | KCa2.1 | ||||||||||||||||||||||||
| 基因和蛋白信息 |
|
||||||||||||||||||||||||
| OMIM | 600244 (Hs) | ||||||||||||||||||||||||
| UniProtKB | Q15116 (Hs) , Q02242 (Mm) | ||||||||||||||||||||||||
| Ensembl Gene | ENSG00000188389 (Hs) , ENSMUSG00000026285 (Mm) , ENSRNOG00000019043 (Rn) | ||||||||||||||||||||||||
| RefSeq Nucleotide | NM_005018 (Hs) , NM_001106927 (Rn) , NM_008798 (Mm) | ||||||||||||||||||||||||
| RefSeq Protein | NP_005009 (Hs) , NP_001100397 (Rn) , NP_032824 (Mm) | ||||||||||||||||||||||||
| Entrez Gene | 5133 (Hs) , 301626 (Rn) , 18566 (Mm) | ||||||||||||||||||||||||
| Protein GI | 167857792 (Hs) , 6679239 (Mm) , 157817590 (Rn) | ||||||||||||||||||||||||
| CATH/Gene3D | 2.60.40.10 (N/A) | ||||||||||||||||||||||||
| ChEMBL Target | CHEMBL3307223 (Hs) , CHEMBL4630756 (Mm) |
| Ligand ID | 7335 |
|---|---|
| 名称 | nivolumab |
| 别名 | BMS-936558 |
| 类别 | Antibody |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
| 评价 |
Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 |
| 配体家族 | Immune checkpoint modulators |
| 单字母多肽序列 | |
| 三字母多肽序列 | |
| 翻译后修饰 | |
| 化学修饰 | |
| 临床描述 |
The first part of the study is the Dose Escalation Phase designed to establish the safety of nivolumab at different dose levels for each of the three cohorts (uninfected hepatocellular carcinoma (HCC) subjects, hepatitis C virus (HCV)-infected HCC subjects, and hepatitis B virus (HBV)-infected subjects). The second part of the study is the Expansion Phase designed to generate additional clinical data at specified doses for each of the 3 cohorts. A third cohort has been added in this study to compare the efficacy of nivolumab and sorafenib in the treatment of Advanced HCC. A fourth cohort will generate data on the safety and efficacy of the combination nivolumab plus ipilimumab in the treatment of Advanced HCC. In the fifth cohort, additional clinical data will be generated for Child-Pugh B subjects. A Cabozantinib Combination Cohort has been added to evaluate the safety and tolerability of nivolumab in combination with cabozantinib and nivolumab with ipilimumab in combination with cabozantinib. The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone. The primary purpose of this study is to compare the objective response rate, as determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab monotherapy in patients with untreated, unresectable, or metastatic melanoma The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer. |
| 来源公司 |
Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb |
| 1. Janakiram M, Abadi YM, Sparano JA, Zang X. (2012) T cell coinhibition and immunotherapy in human breast cancer.. Discov Med, 14 (77): (229-36). [PMID:23114578] |
| 2. Greaves P, Gribben JG. (2013) The role of B7 family molecules in hematologic malignancy.. Blood, 121 (5): (734-44). [PMID:23223433] |
| 3. Tang PA, Heng DY. (2013) Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.. Curr Oncol Rep, 15 (2): (98-104). [PMID:23263823] |
| 4. Hamid O, Carvajal RD. (2013) Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.. Expert Opin Biol Ther, 13 (6): (847-61). [PMID:23421934] |
| 5. Intlekofer AM, Thompson CB. (2013) At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.. J Leukoc Biol, 94 (1): (25-39). [PMID:23625198] |
| 6. Callahan MK, Wolchok JD. (2013) At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.. J Leukoc Biol, 94 (1): (41-53). [PMID:23667165] |
| 7. O'Sullivan Coyne G, Madan RA, Gulley JL. (2014) Nivolumab: promising survival signal coupled with limited toxicity raises expectations.. J Clin Oncol, 32 (10): (986-8). [PMID:24590655] |
| 8. Luke JJ, Ott PA. (2015) PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma.. Oncotarget, 6 (6): (3479-92). [PMID:25682878] |
| 9. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.. N Engl J Med, 372 (21): (2006-17). [PMID:25891304] |
| 10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.. N Engl J Med, 373 (1): (23-34). [PMID:26027431] |
| 11. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al.. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.. N Engl J Med, 373 (19): (1803-13). [PMID:26406148] |
| 12. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.. N Engl J Med, 378 (14): (1277-1290). [PMID:29562145] |
| 13. Pardoll DM. (2012) The blockade of immune checkpoints in cancer immunotherapy.. Nat Rev Cancer, 12 (4): (252-64). [PMID:22437870] |
| 14. Topalian SL, Drake CG, Pardoll DM. (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy.. Cancer Cell, 27 (4): (450-61). [PMID:25858804] |
Nivolumab (anti-PD-1) (N411994) - Flow Cytometry
Flow Cytometry analysis of PHA-stimulated (3 days) human peripheral blood mononuclear lymphocytes labelling PD-1 (red) with Nivolumab (anti-PD-1) (N411994). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Nivolumab (anti-PD-1) (N411994) - SEC
The purity of Nivolumab (anti-PD-1) (N411994) is more than 95% verified by HPLC.
首页
400-620-6333
危险品化学品经营许可证（带存储）